This video provides an in depth technical demonstration of the “PARC data stewardship wizard (DSW)”, the tool PARC projects should use to document their project specific data management plans. An additional video is available explaining PARC Data Management Plans /DSW at more generic level (“Parc Data Management/Plan Data Stewardship Wizard Instruction Video”).

This video provides an overview why PARC in general and PARC projects in particular should implement data management plans (DMP). Further, the advantages of using reference FAIR implementation Profiles, the selection of Data Stewardship Wizard as DMP tool for PARC and important aspects towards getting started with DSW are explained. An additional video is available demonstrating the PARC data stewardship wizard in more detail (“PARC_Data Stewardship Wizard walkthrough”).

This presentation explores the production and use of certified reference materials for human biomonitoring, highlighting practical aspects of method validation, sample stability, and traceability in support of EU chemical risk assessment efforts.

Focuses on key ethical and legal considerations involved in the collection of health information. It provides an introduction to the regulatory frameworks that govern the use of health data, highlighting the importance of accountability and compliance in research.

Recording from Venice School 2025 provides an introduction to Life Cycle Assessment, highlighting essential methodologies and practical insights for evaluating environmental impacts across a product's lifecycle.

Recording of a Venice School 2025 session introducing a case-specific, quantitative MCDA approach for SSbD. It features methods for identifying multi-optimal solutions and integrating stakeholder perspectives in decision-making.

Focuses on showcasing FAIR data collections through the use of dashboards, highlighting how persistent identifiers (PIDs), well-structured metadata, and institutional data presentation can enhance transparency, accessibility, and reuse.

This workshop introduces Safe and Sustainable by Design (SSbD) scenarios for advanced and incremental innovations, focusing on tailored approaches for chemical and material risk assessment.

This video introduces the Safe-and-Sustainable-by-Design (SSbD) approach in developing nano- and micro-pellets or capsules for cosmetics. Focusing on improved efficacy, controlled release, and sustainable material design.

This video introduces the SSbD framework for University students and researchers, detailing its role in guiding safe and sustainable research and innovation.

The Data Management Tool developed for the INTEGRANO project is presented, highlighting its capacity to manage experimental and logistical data, support FAIR principles, and facilitate collaboration among research partners.

This video introduces the Safe and Sustainable by Design (SSbD) framework for the European textile industry, highlighting strategies for sustainability, regulatory compliance, and innovation across the supply chain.

This video presents an overview of SSbD in the cosmetics sector, focusing on innovation, supply chain impacts, and risk assessment of ingredients and processes.

In this video an introduction to the SSbD Framework is provided, highlighting strategies for integrating safety and sustainability into research and innovation.

Key features of SSbD in wastewater treatment are discussed, including material synthesis, process efficiency, adaptability, and collaboration among stakeholders.

This webinar explores the exposome framework in toxicology, focusing on multi-stressor interactions, long-term effects, and regulatory implications for environmental health.

Outlines key concepts in toxicological risk assessment, including critical effects, guidance values, toxicokinetics, and uncertainty factors used in public health decision-making.

Presents Canada’s OHARA initiative to operationalize a One Health approach to risk assessment, emphasizing multisectoral coordination, environmental integration, and protocol development.

Covers the role of industrial toxicology in regulatory compliance, product stewardship, and risk-based evaluation across sectors including chemicals, pharmaceuticals, and consumer goods.

Focused on the Safe(r) and Sustainable Innovation Approach (SSIA), this resource explores the integration of safety and sustainability into material design, regulatory anticipation, and collaborative knowledge-sharing frameworks to keep pace with rapid material innovation.

An overview of risk assessment methodology, emphasizing the steps from hazard identification to exposure characterization and the use of scientific evidence in defining safety thresholds.

A European perspective on workplace risk assessments, featuring presentations on legislation, behavioral approaches, and the OiRA tool to support micro and small businesses.

This seminar discusses in vitro tools to assess toxicology of chemical mixtures.

Presents industry perspectives on QSAR and read-across for regulatory toxicology, focusing on genotoxicity assessment of pesticide residues and the integration of chemical similarity, metabolism, and structural alerts.

Introduces next-generation PBK modeling and its role in translating in vitro concentrations to human-relevant exposures for risk assessment, highlighting key parameters, tools, and case studies.

The webinar focus on methods to evaluate combined exposures and chemical mixtures, using computer models and in vivo/in vitro testing.

Explores the concept, misconceptions, and future potential of AOPs in predictive toxicology, featuring case studies from nanosafety and discussing their integration with data-driven and high-throughput strategies.

Introduces the fundamentals of deep learning and its application in toxicology, with a focus on model construction, input data handling, and potential uses such as QSAR enhancement.

Discusses the potential of non-animal models to transform safety assessment and therapeutic development, with insights from pandemic-driven advances in regulatory science.

Presents the RACE tool, supporting exposure assessment for food contaminants by comparing intake estimates with health-based guidance values.

This presentation provides a brief overview of key human biomonitoring (HBM) initiatives worldwide, offering insight into their scope and objectives. It includes a short introduction to the HBM4EU project, highlighting its role in coordinating efforts across Europe to advance the use of HBM in environmental health research and policymaking.

This presentation focuses on the core objectives of the HBM4EU project, providing a comprehensive overview of how each objective aligns with the project's work package structure. It highlights the strategic organisation of HBM4EU's activities and illustrates how the objectives collectively support the development of a coherent and policy-relevant human biomonitoring framework across Europe.

This presentation focuses on the use of blood and urine as primary biological media in HBM, outlining key characteristics of selected biomarkers in each matrix. It provides practical guidance on sample collection methods, highlighting potential pitfalls and necessary contingencies. Strategies for aliquoting and storage are discussed in detail, emphasising the importance of maintaining homogeneity in urine samples and the role of fractionation in sample pretreatment. Considerations for storage conditions, including cooling, freezing, and the use of preservatives, are also addressed to ensure sample integrity.

This presentation focuses on the role of human biomonitoring (HBM) in enhancing chemical risk assessment and supporting evidence-based policymaking. It highlights the need for reliable data on human exposure to chemicals across the EU, including variations over time, geography, and population sub-groups. The presentation also explores how HBM can inform policy by providing tools to interpret exposure data, assess health impacts, and monitor patterns and trends in chemical exposure across Europe.

This presentation focuses on the concept and principles of Human Biomonitoring, specifically the classification and application of biomarkers, distinguishing between those used for exposure assessment, susceptibility evaluation, and research purposes. Highlights how the selection of specific biomarkers can provide insights into bioavailability and bioactivation over time, making them valuable tools for assessing aggregate exposure in diverse populations.

This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.

This presentation focuses on the fundamental terminology and principles of sampling, providing a clear overview of key concepts essential for designing and conducting human biomonitoring studies. It includes a brief introduction to the sample selection strategy developed for HBM4EU alignment studies.

This presentation focuses on the basic principles of matrix and biomarker selection in human biomonitoring, guiding participants from the identification of exposure biomarkers to their application in population studies. 

Focuses on the health risks associated with asbestos exposure, emphasizing its link to a range of diseases including asbestosis, pleural conditions, and multiple forms of cancer. Highlights malignant mesothelioma as a particularly aggressive cancer of the pleura and peritoneum, primarily caused by asbestos exposure. Discusses current challenges in diagnosing mesothelioma and the ongoing investigation into potential serum biomarkers, such as Soluble Mesothelin Related Protein (SMRP), Fibulin-3, and Survivin, for improving early detection and monitoring treatment response.

Focuses on exploring the role of gene-environment interactions in disease development, using asbestosis as a case study to illustrate the combined impact of genetic and environmental factors. Highlights findings from a nested case-control study that incorporated cumulative asbestos exposure, smoking data, and PCR-based genotyping, with logistic regression used to assess risk. Emphasises the importance of investigating how genetic factors interact with lifestyle and occupational exposures to shape disease outcomes.

Introduces the Safe Innovation Approach, combining Safe by Design and Regulatory Preparedness to address safety early in the innovation process, with a focus on nanomaterials.

This SOP focuses on standardising dermal exposure assessment to total chromium through wipe sampling, based on established IOM procedures and OSHA Method ID-125G guidelines. The protocol utilises SKC Ghost wipes to collect representative samples of hand contamination, supporting consistent and reliable monitoring of metals such as chromium, zinc, nickel, and hydrocarbons across different exposure scenarios.